InvestorsHub Logo
Followers 12
Posts 1019
Boards Moderated 0
Alias Born 03/24/2013

Re: jbog post# 17240

Thursday, 05/18/2017 12:23:53 AM

Thursday, May 18, 2017 12:23:53 AM

Post# of 20689
1. $1.5b is too cheap for the only apparent contender that can potentially achieve interchangeability with Humira (selling $16b/year)

2. Rest of the pipe is worth as much as item 1, IMO.

You see, it's difficult to agree on a valuation.